Nocimed has been issued a patent from the U.S. Patent and Trademark Office related to the company's technology using nuclear MR spectroscopy to evaluate pain and degenerative properties of tissue.
Another related patent was recently granted in Australia, the firm said. In addition, other related patent applications are pending in other major territories outside of the U.S.
The issued patents and pending applications are owned by the regents of the University of California via the original inventors at University of California, San Francisco and are licensed exclusively to Nocimed.
